Journal article
Validity of the Adult ADHD Self-Report Scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients
Geurt van de Glind, Wim van den Brink, Maarten WJ Koeter, Pieter-Jan Carpentier, Katelijne van Emmerik-van Oortmerssen, Sharlene Kaye, Arvid Skutle, Eli-Torild H Bu, Johan Franck, Maija Konstenius, Franz Moggi, Geert Dom, Sofie Verspreet, Zsolt Demetrovics, Mate Kapitany-Foeveny, Melina Fatseas, Marc Auriacombe, Arild Schillinger, Andrea Seitz, Brian Johnson Show all
DRUG AND ALCOHOL DEPENDENCE | ELSEVIER IRELAND LTD | Published : 2013
Abstract
BACKGROUND: To detect attention deficit hyperactivity disorder (ADHD) in treatment seeking substance use disorders (SUD) patients, a valid screening instrument is needed. OBJECTIVES: To test the performance of the Adult ADHD Self-Report Scale V 1.1(ASRS) for adult ADHD in an international sample of treatment seeking SUD patients for DSM-IV-TR; for the proposed DSM-5 criteria; in different subpopulations, at intake and 1-2 weeks after intake; using different scoring algorithms; and different externalizing disorders as external criterion (including adult ADHD, bipolar disorder, antisocial and borderline personality disorder). METHODS: In 1138 treatment seeking SUD subjects, ASRS performance wa..
View full abstractGrants
Funding Acknowledgements
[ "For coordination of the IASP study, as described in the acknowledgement part of the manuscript, grants were received from pharmaceutical companies (Shire, Eli Lilly & Company, Jansen Cilag), from participating institutes and from three not for profit organizations: the Waterloo Foundation, the Noaber Foundation and the Augeo Foundation.", "G. Van de Glind was on one occasion consultant for Shire, for which he refused payment. He is (unpaid) member of the advisory board of Neurotech. P.-J. Carpentier received in 2011 fee for speaking at a conference organized by Eli Lilly. F.R. Levin reports Study Medication provided by US World Meds; Consultant to GW Pharmaceuticals. The ICASA Foundation has reimbursed her for air-fare to attend the Annual Meeting as a speaker. In the past year, S.V. Faraone received consulting income and/or research support from Shire, Otsuka and Alcobra and research support from the National Institutes of Health (NIH). He is also on the Clinical Advisory Board for Akili Interactive Labs. In previous years, he received consulting fees or was on Advisory Boards or participated in continuing medical education programs sponsored by Shire, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. S.V. Faraone receives royalties from books published by Guilford Press: Straight Talk about Your Child's Mental Health and Oxford University Press: Schizophrenia: The Facts. Z. Demetrovics has received research grant from Schering-Plough for research on Suboxone maintenance therapy (2009) and has received reimbursement for participating at a symposia organized by Lundbeck (2011). G. Dom acted as a paid consultant for Lundbeck and received speakers fee and reimbursement for symposium attendance from GSK, Janssen Ph., Astra-Zeneca, Eli Lilly. J. Franck declares his research group received an unrestricted research grant from Jansen Cilag in 2007. The grant was received and administered by his university (Karolinska Institutet). W. van den Brink has received a fee from Eli Lilly for organizing a symposium on the role of impulsivity in psychiatric disorders and a speaker's fee from Eli Lilly for a presentation on the relationship between ADHD and addiction. The above mentioned authors and the other authors declare, apart from the funding resources mentioned in the acknowledgement section, no other conflicts of interest." ]